Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glaucoma; Drugs Clear all
Withdrawn Not applicable Interventional

Omega 3 Supplementation and Ocular Surface Disease in Glaucoma

NCT01630551
View directory record Official record
Conditions
Ocular Surface Disease
Interventions
Fishoil supplement, Olive Oil
Dietary Supplement
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 19, 2026, 4:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

NCT01157364
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2, bimatoprost 6 µg generation 2, bimatoprost 15 µg generation 1, bimatoprost 10 µg generation 1, bimatoprost 0.03%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
36
States / cities
Artesia, California • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Sep 19, 2026, 4:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

NCT03896633
View directory record Official record
Conditions
Glaucoma, Open Angle or Ocular Hypertension
Interventions
brinzolamide 1% ophthalmic suspension, Azopt 1%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 19, 2026, 4:13 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

NCT04354545
View directory record Official record
Conditions
Glaucoma, Ocular Surface Disease
Interventions
Xiidra (Lifitegrast ophthalmic solution) 5%
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Fountain Valley, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 19, 2026, 4:13 AM EDT
Terminated Phase 1 Interventional

Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension

NCT04500574
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Latanoprost eluting contact lens, Topical Latanoprost
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 19, 2026, 4:13 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Glaucoma Drop Aids in Medication Compliance in the Patient Population at Boston Medical Center

NCT02867995
View directory record Official record
Conditions
Glaucoma
Interventions
Eye Drop Aid
Device
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 19, 2026, 4:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®

NCT00799682
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Xalatan, Travatan Z
Drug
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
5
States / cities
East Meadow, New York • Lynbrook, New York • Rockville Centre, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Sep 19, 2026, 4:13 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Real-time Glaucoma Medication Adherence

NCT03194828
View directory record Official record
Conditions
Glaucoma
Interventions
Medication reminder, Medication monitoring only
Behavioral
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
8
States / cities
Augusta, Georgia • Grovetown, Georgia • Louisville, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 19, 2026, 4:13 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?

NCT06369077
View directory record Official record
Conditions
Glaucoma, Open-Angle, Glaucoma; Drugs
Interventions
dorzolamide/timolol
Drug
Lead sponsor
CT Glaucoma Associates
Other
Eligibility
25 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 19, 2026, 4:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications

NCT03506568
View directory record Official record
Conditions
Medication Adherence, Glaucoma
Interventions
Devers Drop Device (D3) app
Device
Lead sponsor
Universal Adherence LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 19, 2026, 4:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)

NCT00698945
View directory record Official record
Conditions
Ocular Hypertension, Open-Angle Glaucoma
Interventions
Istalol and Optive, Alphagan
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Petaluma, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2008 · Synced Sep 19, 2026, 4:13 AM EDT
Completed Phase 1Phase 2 Interventional

Novel Drug Delivery Technique Via Retroject Device

NCT02051946
View directory record Official record
Conditions
Glaucoma
Interventions
Retroject Device, ethacrynic acid injection, balanced salt solution
Device · Drug
Lead sponsor
Molly Walsh
Other
Eligibility
55 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Sep 19, 2026, 4:13 AM EDT
Completed Phase 2 Interventional

Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101

NCT02656394
View directory record Official record
Conditions
Ocular Surface Disease
Interventions
GL101, Placebo
Drug
Lead sponsor
Glia, LLC
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Sep 19, 2026, 4:13 AM EDT
Completed No phase listed Observational

Survey of Patients Taking IOP-Lowering Eye Drops

NCT02384772
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Survey
Other
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
Not listed
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Sep 19, 2026, 4:13 AM EDT
Completed No phase listed Observational Results available

A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs

NCT00823043
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
timolol hemihydrate, timolol maleate
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 19, 2026, 4:13 AM EDT
Withdrawn Not applicable Interventional

IOP and Medication Reduction in MIGS Procedures

NCT04202510
View directory record Official record
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma in Both Eyes
Interventions
Glaucoma and Cataract Surgery
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 19, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a Drug Delivery System in Glaucoma

NCT01016691
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03%
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Mt. Pleasant, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 19, 2026, 4:13 AM EDT
Completed Not applicable Interventional Results available

The Support, Educate, Empower (SEE) Program

NCT04735653
View directory record Official record
Conditions
Glaucoma
Interventions
Personalized Glaucoma Coaching, Enhanced Standard care
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Sep 19, 2026, 4:13 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Sep 19, 2026, 4:13 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Anti-Glaucoma Medications on the Ocular Surface

NCT01315574
View directory record Official record
Conditions
Glaucoma
Interventions
Travoprost, Latanoprost
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 19, 2026, 4:13 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

CATS Tonometer IOP Reduction Latanoprost Verses Timolol

NCT04178863
View directory record Official record
Conditions
Glaucoma; Drugs
Interventions
CATS Tonometer, Latanoprost
Device · Drug
Lead sponsor
Intuor Technologies, Inc.
Industry
Eligibility
18 Years to 101 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Sep 19, 2026, 4:13 AM EDT
Withdrawn Phase 1 Interventional

iDropper Usability in Glaucoma

NCT02031380
View directory record Official record
Conditions
Glaucoma, Open-Angle [C11.525.381.407]
Interventions
Open angle glaucoma - iDropper device
Device
Lead sponsor
Care Team Solutions
Industry
Eligibility
21 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Sep 19, 2026, 4:13 AM EDT
Not yet recruiting Phase 4 Interventional

The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients

NCT04007276
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open-Angle, Glaucoma; Drugs, Droopy Eyelid, Ptosis, Glaucoma, Primary Open Angle
Interventions
brimonidine tartrate ophthalmic solution 0.025%, sterile balanced saline solution
Drug · Other
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 19, 2026, 4:13 AM EDT
Not yet recruiting Not applicable Interventional

DSLT in Normal Tension Glaucoma (NTG) Asian Eyes

NCT07300852
View directory record Official record
Conditions
Normal Tension Glaucoma (NTG), Glaucoma, Open Angle Glaucoma (OAG), Glaucoma, Open Angle
Interventions
Direct Selective Laser Trabeculoplasty (DSLT)
Device
Lead sponsor
Ngoc Nguyen Inc.
Other
Eligibility
20 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 19, 2026, 4:13 AM EDT